 |
5 Products |  |
63 Diseases | | 5 Products |
|
156 Trials |  |
7159 News |  |
| «12345678910111213...8081» |
- Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION AFTER GVHD PROPHYLAXIS WITH REDUCED ANTI-T LYMPHOCYTE GLOBULIN DOSES (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3106;
Aims: This retrospective study aimed to evaluate the outcomes of allo-SCT with reduced ATLG Grafalon
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
COMPARISON OF RABBIT ANTI-THYMOCYTE GLOBULINS (ATG-T) AND ANTI-T-LYMPHOCYTE GLOBULINS (ATLG) IN TBI-BASED MAC OF ALTERNATIVE DONOR HSCT FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3048;
Additionally, it lowers the occurrences of EBV-viremia, PTLD, and HumanParvovirus B19-viremia while maintaining comparable post-transplant efficacy. Based on these outcomes, ATLGemerges as a preferred choice for GVHD prophylaxis in ALL patients who received alternative HSCT with TBI-based MAC, provided it is accessible.
- Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
MISMATCHED UNRELATED DONORS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH ANTITHYMOCYTE GLOBULIN FOR HEMATOLOGICAL MALIGNANCIES: A MULTICENTER RETROSPECTIVE STUDY IN CHINA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3036;
In conclusion, MMUD allo-HSCT with ATG demonstrates favorable outcomes for patients with hematologicalmalignancies, with no evident correlation between the degree of mismatch and post-transplantation results. Utilizing a lower dose of ATG-G proved efficacious, delivering comparable clinical advantages while reducingcosts and infection risks.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
CYCLOPHOSPHAMIDE-CONTAINING GVHD PROPHYLAXIS FOR RECIPIENTS OF UNRELATED DONOR HSCT IMPROVES GVHD-FREE, DISEASE-FREE OUTCOME IN PEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3024;
GvHD prophylaxisstrategies involved the administration of a calcineurin inhibitor in conjunction with either postCy in 16 patients(7 MUD and 9 MMUD) or a regimen of methotrexate and mycophenolate mofetil in 10 patients (5 MUD and 5MMUD)...Conversely, the cohort not treated with postCy developing advanced grades aGvHD demonstratedlimited response to an immunosuppressive regime consisting primarily of a calcineurin inhibitor, infliximab,ruxolitinib and extracorporeal photophoresis, with one individual showing minimal response over nearly twoyears after HSCT... These findings contribute to the development of safer, more accessible therapeutic regimens including 9/10matched unrelated donor transplantation, which are pivotal for patients lacking matched familial or HLA-compatible donors.
- Xpovio (selinexor) / Karyopharm
PHASE 2 STUDY EVALUATING EFFICACY AND SAFETY OF SELINEXOR MONOTHERAPY IN PATIENTS WITH JAKI-NA () - May 15, 2024 - Abstract #EHA2024EHA_2871;
P2, P3
None. Trial in progress.
- Jakafi (ruxolitinib) / Incyte, Xpovio (selinexor) / Karyopharm
PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY EVALUATING SAFETY AND EFFICACY OF SELINEXOR, AN XPO1 INHIBITOR, PLUS RUXOLITINIB IN JAKI-NA () - May 15, 2024 - Abstract #EHA2024EHA_2852;
P3
None. Trial in progress.
- Jakafi (ruxolitinib) / Incyte, Xpovio (selinexor) / Karyopharm
SELINEXOR PLUS RUXOLITINIB IMPACT ON SYMPTOM BURDEN IN PATIENTS WITH MYELOFIBROSIS AND POTENTIAL MECHANISM OF ACTION VIA INHIBITION OF NF-?B AND ACTIVATION OF P53 PATHWAYS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2823;
P3
Sel+Rux was generally well-tolerated, with signals of reduced symptom burden and spleen reduction both ofwhich were durable. The in vitro results point to a potential mechanism of action in which XPO1 inhibitiontargets multiple oncogenic pathways beyond JAK-STAT, including inhibition of NF-?B-driven proinflammatorycytokine production and p53-mediated cell cycle regulation leading to apoptosis.
- Xpovio (selinexor) / Karyopharm
SELINEXOR AND MELPHALAN CONDITIONING REGIMEN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA () - May 15, 2024 - Abstract #EHA2024EHA_2620;
2% received daratumumab. Our findings suggest that the combination of selinexor with melphalan could optimize the ASCT efficiency, andwas well tolerated and engraftment kinetics were not altered.
- Xpovio (selinexor) / Karyopharm
SELINEXOR COMBINED BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD) () - May 15, 2024 - Abstract #EHA2024EHA_2587;
P1/2
It is worthy offurther study based on the preliminary efficacy results. Longer-term results still require more pts have beenenrolled and further follow-up.
- Xpovio (selinexor) / Karyopharm
NOVEL SELINEXOR TRIPLET AND QUADRUPLET REGIMENS (SND, SPED, SBD, SDPD): RESULTS FROM THE PHASE 1B/2 STOMP MULTIPLE MYELOMA TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2582;
P1/2
The majority of pts tolerated the selinexor regimensat the intended dosing. No increase in partner drug toxicities were observed, which aligns with thecombinability profile of selinexor + dexamethasone with carfilzomib (SKd), pomalidomide (SPd), anddaratumumab (SDd) in the STOMP study.
- Xpovio (selinexor) / Karyopharm
OUTCOMES WITH SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): REGIONAL SUBGROUP ANALYSIS OF THE PHASE 3 BOSTON TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2475;
P3
Some of thesedifferences may have contributed to the favorable efficacy reported with SVd for pts in R1-3. Undescribeddifferences in clinical care and patient education may also have contributed to outcomes.
- Xpovio (selinexor) / Karyopharm
TARGETING XPO1 AND PRL-3 INDUCED MITOCHONDRIAL DAMAGE AND APOPTOSIS IN MDS THERAPY () - May 15, 2024 - Abstract #EHA2024EHA_2216;
Undescribeddifferences in clinical care and patient education may also have contributed to outcomes. We demonstrate that Selinexor combined with PRL-3 inhibitors is a potentially effective way to treat MDS.
- Farydak (panobinostat) / Secura Bio
PANOBINOSTAT AND PIM-2 INHIBITORS PROMOTE THE APOPTOSIS OF MDS/AML MALIGNANT CELLS BY INHIBITING THE NF-?B PATHWAY () - May 15, 2024 - Abstract #EHA2024EHA_2214;
Figure. A.
- Xpovio (selinexor) / Karyopharm
XPO1 INHIBITOR TRIGGERS AUTOPHAGY OF TP53-MUTATED BURKITT LYMPHOMA CELLS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2118;
A. XPO1 Inhibitor, KPT330 can restrict nuclear export of autophagy-related proteins, thus regulating autophagyand stabilizing p53 function in TP53-mutated Burkitt lymphoma cells, which revealed a promising treatment.
- Xpovio (selinexor) / Karyopharm
COMBINATION OF SELINEXOR WITH BTK INHIBITOR FOR CENTRAL NERVOURS SYSTEM DIFFUSE LARGE B-CELL LYMPHOMA, POSSIBLE MECHANISMS AND THERAPEUTIC POTENTIAL EXPLORATION (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2103;
Correspondingly, in treatment of centralDLBCL patients, the novel therapeutic strategy of MSZ regimen has achieved impressive results, with a CRR of100%. Most patients attained early and rapid deep remissions with durable efficacy.
- eltanexor (KPT-8602) / Karyopharm, Xpovio (selinexor) / Karyopharm
INHIBITION OF NUCLEAR EXPORT PROMOTES EXPANDED NK CELL AND ANTI-CD19 CAR NK CELL LYSIS OF MALIGNANT B CELLS VIA DISRUPTION OF NKG2A (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_2067;
P1/2
Additionally,anti-CD19 CAR NK cell cytotoxicity was enhanced with selinexor. This effect occurs via downregulation of HLA-E and release of inhibitory NKG2A signaling.
- Xpovio (selinexor) / Karyopharm, Rituxan (rituximab) / Roche
XPO-1 INHIBITOR SELINEXOR IN COMBINATION WITH RCHOP IS AN EFFECTIVE CHEMOTHERAPY REGIMEN FOR PATIENTS WITH DOUBLE/TRIPLE-HIT LARGE B-CELL LYMPHOMA. () - May 15, 2024 - Abstract #EHA2024EHA_1559;
Dynamic testing of ctDNA also demonstrated deep remission to chemotherapy. Based on the encouragingresults of the current study, a large scale, multicenter trial is needed to further investigate this promisingregimen.
- Xpovio (selinexor) / Karyopharm
PHASE 2 SEARCH STUDY:SELINEXOR (ATG-010) MONOTHERAPY IN HEAVILY PRETREATED CHINESE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA () - May 15, 2024 - Abstract #EHA2024EHA_1551;
P2
The SEARCH study demonstrated a clinically meaningful ORRin Chinese R/R DLBCL pts treated with selinexor monotherapy, consistent with the global study. Adverse eventswere generally manageable with appropriate supportive care and dose modification.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Xpovio (selinexor) / Karyopharm
SELINEXOR COMBINED WITH TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA (R/R ENKTL): RESULTS OF DOSE ESCALATION OF COHORT C FROM PHASE I/II STUDY TOUCH () - May 15, 2024 - Abstract #EHA2024EHA_1545;
P1/2
Selinexor in combination of tislelizumab showed tolerable safety profile across 2 doselevels and promising efficacy results in R/R ENKTL. Expansion stage of Cohort C is ongoing.
- Xpovio (selinexor) / Karyopharm
SELINEXOR IN COMBINATION WITH R-EPOCH FOR PATIENTS WITH PREVIOUSLY UNTREATED HIV-ASSOCIATED DIFFUSE LARGE B CELL LYMPHOMA(DLBCL) () - May 15, 2024 - Abstract #EHA2024EHA_1472;
The change of HIV RNA load and CD4+ cell count still requires furtherevaluation. Figure 1 Patients treatment in the cohorts.
- Venclexta (venetoclax) / Roche, AbbVie, Xpovio (selinexor) / Karyopharm
THE EFFICACY AND SAFETY OF SELINEXOR COMBINED WITH VENETOCLAX FOR UNTREATED ELDERLY UNFIT ACUTE MYELOID LEUKEMIA (AML) () - May 15, 2024 - Abstract #EHA2024EHA_1252;
The combination of selinexor and venetoclax has been found to be safe and effective, with encouragingcomplete response (CR) rates in untreared elderly unfit AML pts, especially in adverse-risk patients. Furthermulticenter trial study are underway to thoroughly observe the efficacy and safety of the regimen.
- Venclexta (venetoclax) / Roche, AbbVie, Epidaza (chidamide) / Chipscreen, Xpovio (selinexor) / Karyopharm
SELINEXOR AND CHIDAMIDE TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA EXPOSED TO VENETOCLAX: A SINGLE-ARM, PHASE 2 STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1125;
P2
In this study, the combination of selinexor and chidamide was administered as a salvage treatment for R/RAML patients, and it resulted in a high response rate and favorable safety profile. This treatment offers apotential way for patients to bridge to transplantation; however, future studies with larger sample sizes andlonger follow-up periods are required to further validate its efficacy.
- Venclexta (venetoclax) / Roche, AbbVie, Xpovio (selinexor) / Karyopharm
SELINEXOR COMBINATION WITH DECITABINE AND HALF-DOSE CMG (CYTARABINE+ MITOXANTRONE+G-CSF) IN PATIENTS WITH R/R AML PREVIOUSLY EXPOSED TO VENETOCLAX:A SINGLE-CENTER RETROSPECTIVE STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1118;
Presently, Selinexor-based regimens are also being used in lymphoma, solid tumors and leukemiasalvage treatments. From the retrospective study of 8 patients, the salvage treatment regimen based onSelinexor, Decitabine and half-dose CMG in patients with R/R AML previously exposed to venetoclax,demonstrated an overall response rate (ORR) of 75%.
- omipalisib (GSK2126458) / GSK, Xpovio (selinexor) / Karyopharm
COMBINATION OF SELINEXOR WITH PI3K/MTOR DUAL INHIBITOR OMIPALISIB EXHIBITS SYNERGISTIC EFFECTS IN ACUTE MYELOID CELLS WITH DIFFERENT GENETIC BACKGROUND IN VITRO AND IN VIVO (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_932;
From the retrospective study of 8 patients, the salvage treatment regimen based onSelinexor, Decitabine and half-dose CMG in patients with R/R AML previously exposed to venetoclax,demonstrated an overall response rate (ORR) of 75%. The combination of selinexor and omipalisib had synergistic effects on both OCI-AML3 and SKNO-1 myeloidleukemia cells with different genetic background, indicating that this combination had beneficial fortherapeutic strategy in heterogeneous myeloid leukemias.
- | Mekinist (trametinib) / Novartis, BeiGene, Tagrisso (osimertinib) / AstraZeneca, Xpovio (selinexor) / Karyopharm, FORUS Therap
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. (Pubmed Central) - May 14, 2024
Selinexor with a PD-1 inhibitor with or without trametinib abrogates the tumor growth in the murine Lewis lung cancer model. An in-depth exploration of the functions of HMGB1 mRNA and protein is expected to uncover new potential targets and provide a basis for treating metastatic NSCLC in combination with ICI.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
The interpretation of the anti-HLA-A3 appearance after treatment with anti-thymocyte globulin () - May 12, 2024 - Abstract #EFI2024EFI_304;
We report the case of identification of de novo anti-HLA-A3 antibody in a 47 year old male patient who underwent his second living kidney transplantation receiving an HLA-A3 graft, treated with ATG (Grafalon, Neovii Biotech GmbH)...In the meantime, the function of the graft improved and the patient was discharged from the hospital. This kind of influence of ATG on antibody testing has been described in the literature so far and this fact should always be kept in mind when interpreting the anti-HLA antibodies results.
- | Xpovio (selinexor) / Karyopharm, FORUS Therap
Journal, IO biomarker: Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia. (Pubmed Central) - May 11, 2024
In conclusion, this study revealed the resistance mechanism of selinexor in CML. In conclusion, we identified a subgroup of CML cells with tumor stem cell properties and demonstrated that ferroptosis inducer improved the efficacy of selinexor in overcoming drug resistance.
- | Brukinsa (zanubrutinib) / BeiGene, Xpovio (selinexor) / Karyopharm, FORUS Therap
Journal, Biopsy: Zanubrutinib delays selinexor resistance evolution in biopsy sample-derived primary central nervous system lymphoma models. (Pubmed Central) - May 10, 2024
Moreover, selinexor combined with zanubrutinib notably slowed tumor growth and prolonged survival compared to that of the control. Overall, the addition of zanubrutinib to selinexor monotreatment had a synergistic effect in
- |||||| ABBV-383 IV / AbbVie
Enrollment open, Monotherapy: Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 10, 2024
P3, N=380, Recruiting, Sponsor: AbbVie
Overall, the addition of zanubrutinib to selinexor monotreatment had a synergistic effect in Not yet recruiting --> Recruiting
- | Xpovio (selinexor) / Karyopharm
Enrollment open: A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (clinicaltrials.gov) - May 9, 2024
P1/2, N=210, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- | Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - May 8, 2024
P1, N=6, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Active, not recruiting | N=24 --> 6 | Trial primary completion date: Aug 2025 --> Sep 2023
- | 211At-BC8-B10 / Fred Hutchinson Cancer Center
Trial suspension: Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (clinicaltrials.gov) - May 8, 2024
P1/2, N=40, Suspended, Sponsor: Fred Hutchinson Cancer Center
Recruiting --> Active, not recruiting | N=24 --> 6 | Trial primary completion date: Aug 2025 --> Sep 2023 Recruiting --> Suspended
- || Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date: SPRINT: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (clinicaltrials.gov) - May 7, 2024
P1/2, N=120, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Recruiting --> Suspended Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- || Venclexta (venetoclax) / Roche, AbbVie, Xpovio (selinexor) / Karyopharm
Trial primary completion date: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies (clinicaltrials.gov) - May 3, 2024
P1, N=78, Active, not recruiting, Sponsor: Sanjay Mohan
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Trial primary completion date: Mar 2024 --> Sep 2024
- | Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date, Combination therapy: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients (clinicaltrials.gov) - Apr 30, 2024
P2, N=100, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Mar 2024 --> Sep 2024 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- Ninlaro (ixazomib) / Takeda, Xpovio (selinexor) / Karyopharm, FORUS Therap
SELINEXOR, IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN FUNCTIONALLY HIGH-RISK MULTIPLE MYELOMA: RESULTS FROM THE MYELOMA DEVELOPING REGIMENS USING GENOMICS (MYDRUG) SUB-PROTOCOL Y3 (ONLINE ONLY) - Apr 29, 2024 - Abstract #COMy2024COMy_103;
- || Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Review, Journal: Selinexor in multiple myeloma. (Pubmed Central) - Apr 28, 2024
The evolving landscape of selinexor's role in the sequencing of treatment for RRMM, its potential in high-risk patients, including those with extramedullary disease, as revealed in the most recent international meetings, and ongoing investigations signal a dynamic era in myeloma therapeutics. Selinexor emerges as a pivotal component in multidrug strategies and innovative combinations.
- | Relyvrio (phenylbutyrate/taurursodiol) / Amylyx
Enrollment closed, Trial completion date, Trial primary completion date: HELIOS: AMX0035 in Adult Patients With Wolfram Syndrome (clinicaltrials.gov) - Apr 26, 2024
P2, N=12, Active, not recruiting, Sponsor: Amylyx Pharmaceuticals Inc.
Selinexor emerges as a pivotal component in multidrug strategies and innovative combinations. Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Nov 2024 --> Jul 2024
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Journal: Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell Lymphoma Cells (Pubmed Central) - Apr 25, 2024
KPT-330 can inhibit MCL cell proliferation and induce autophagy. KPT-330 combined with autophagy inhibitor CQ could produce synergistic anti MCL effects, providing experimental basis for clinical combination therapy.
- Xpovio (selinexor) / Karyopharm
A phase II clinical trial of selinexor in patients with advanced thymoma and thymic carcinoma. (Hall A; Poster Bd #: 376) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3370;
P2
Selinexor demonstrated modest anticancer activity in patients with pretreated advanced TET. ORRs were low but prolonged stable disease was noted in a subset of patients.
- purinostat / Baoling Bio
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial. (Hall A; Poster Bd #: 57) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2409;
P2
This study further supports the recommended dose 11.2 mg/m 2 PM as the phase 2b for r/r DLBCL. Currently, the phase 2b, open-label, multicenter study has enrolled in 37 sites in China.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Xpovio (selinexor) / Karyopharm
Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH). (Hall A; Poster Bd #: 48) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2400;
P1/2
Selinexor plus tislelizumab showed tolerable safety profile and encouraging response rate in R/R ENKTL. Expansion stage of Cohort C is ongoing.
- Xpovio (selinexor) / Karyopharm
Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis. (Hall A; Poster Bd #: 465) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1906;
P2, P3
The integrated E-R analysis demonstrates the potential for SEL 60 mg QW to be reasonably well-tolerated, while maintaining efficacy. Evaluation of 60 mg SEL QW as maintenance therapy for TP53wt advanced/recurrent EC is ongoing in the phase 3 ENGOT-EN20/GOG-3083/XPORT-EC-042 trial (NCT05611931).
- Xpovio (selinexor) / Karyopharm
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC). (Hall A; Poster Bd #: 461) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1472;
P1/2
Selinexor plus docetaxel is tolerated with multi-agent supportive care. The combination shows moderate efficacy across KRAS mutation types, with promising activity in TP53 wild type cases.
- Jakafi (ruxolitinib) / Incyte, Xpovio (selinexor) / Karyopharm
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-na (Hall A; Poster Bd #: 148b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1229;
P3
The key secondary endpoint is anemia response at Week 24 per the IWG-MRT and ELN criteria. The XPORT-MF-034 Phase 3 trial is currently open for enrollment; a total of 306 JAKi-na
- Xpovio (selinexor) / Karyopharm
Phase 2 study evaluating selinexor monotherapy in patients with JAKi-na (Hall A; Poster Bd #: 148a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1228;
P2, P3
Primary endpoint is SVR35 at week 24. Key secondary endpoints are safety, TSS50 at week 24, anemia response at week 24, overall survival, and overall response rate.
- Xpovio (selinexor) / Karyopharm, Tecentriq (atezolizumab) / Roche
Safety and toxicity evaluation of the combination of selinexor with atezolizumab in patients with soft tissue sarcomas. (Hall A; Poster Bd #: 483) - Apr 24, 2024 - Abstract #ASCO2024ASCO_765;
P2
The treatment was well tolerated. Based on these data, the randomized part of this study began accruing patients with ASPS across the ETCTN (Experimental Therapeutics Clinical Trials Network).
- || Removab (catumaxomab) / NeoPharm, Trion Pharma, Avastin (bevacizumab) / Roche
Review, Journal: Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment. (Pubmed Central) - Apr 22, 2024
Despite these options, no standard treatment for MA has been established yet because few trials have been conducted in this area. There are many issues to be investigated, and future research and treatment development are expected.
- | Neofordex (dexamethasone acetate high-dose) / CTRS Laboratories, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment closed: SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov) - Apr 22, 2024
P2, N=50, Active, not recruiting, Sponsor: Ida Bruun Kristensen
There are many issues to be investigated, and future research and treatment development are expected. Recruiting --> Active, not recruiting
- || Review, Journal: Therapeutic progress in relapsed/refractory multiple myeloma. (Pubmed Central) - Apr 13, 2024
Additionally, novel antibody drugs, such as elotuzumab and selinexor, as well as bispecific antibodies, teclistamab and talquetamab, are currently undergoing clinical research with promising outcomes. However, chimeric antigen receptor-T cell therapy targeting B-cell maturation antigen remains the optimal approach for MM treatment.